UST

Summary

UST (uronyl 2-sulfotransferase, HGNC:17223) is a protein-coding gene on chromosome 6q25.1, encoding Uronyl 2-sulfotransferase (Q9Y2C2). Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to the 2-OH position of uronyl residues in glycosaminoglycan chains.

Uronyl 2-sulfotransferase transfers sulfate to the 2-position of uronyl residues, such as iduronyl residues in dermatan sulfate and glucuronyl residues in chondroitin sulfate (Kobayashi et al., 1999 [PubMed 10187838]).

Source: NCBI Gene 10090 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_005715

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17223
Approved symbol	UST
Name	uronyl 2-sulfotransferase
Location	6q25.1
Locus type	gene with protein product
Status	Approved
Aliases	2OST
Ensembl gene	ENSG00000111962
Ensembl biotype	protein_coding
OMIM	610752
Entrez	10090

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000367463, ENST00000466695, ENST00000473631, ENST00000912224, ENST00000912225

RefSeq mRNA: 1 — MANE Select: NM_005715 NM_005715

CCDS: CCDS5213

Canonical transcript exons

ENST00000367463 — 8 exons

Exon	Start	End
ENSE00000765065	149019139	149019236
ENSE00000765068	149021324	149021481
ENSE00000813604	148953872	148953951
ENSE00001124309	148886986	148887029
ENSE00001129037	148941279	148941434
ENSE00001444568	149073833	149076990
ENSE00001444569	148747030	148747677
ENSE00003619910	148964410	148964563

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 89.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6691 / max 133.1498, expressed in 1508 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
70444	10.3203	1482
70443	0.9614	726
70456	0.2487	47
70446	0.1386	37

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pons	UBERON:0000988	89.73	gold quality
calcaneal tendon	UBERON:0003701	89.60	gold quality
adrenal tissue	UBERON:0018303	89.52	gold quality
tibia	UBERON:0000979	89.23	gold quality
hypothalamus	UBERON:0001898	88.32	gold quality
substantia nigra	UBERON:0002038	87.94	gold quality
sural nerve	UBERON:0015488	87.56	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	87.20	gold quality
thyroid gland	UBERON:0002046	87.17	gold quality
midbrain	UBERON:0001891	87.15	gold quality
left lobe of thyroid gland	UBERON:0001120	86.75	gold quality
right lobe of thyroid gland	UBERON:0001119	86.32	gold quality
spinal cord	UBERON:0002240	86.25	gold quality
skin of hip	UBERON:0001554	86.19	gold quality
synovial joint	UBERON:0002217	85.97	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	85.50	gold quality
substantia nigra pars compacta	UBERON:0001965	85.22	gold quality
stromal cell of endometrium	CL:0002255	84.54	gold quality
dorsal root ganglion	UBERON:0000044	84.03	gold quality
periodontal ligament	UBERON:0008266	83.81	gold quality
body of pancreas	UBERON:0001150	83.13	gold quality
cartilage tissue	UBERON:0002418	82.49	gold quality
trigeminal ganglion	UBERON:0001675	82.35	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.23	gold quality
choroid plexus epithelium	UBERON:0003911	82.11	gold quality
thoracic aorta	UBERON:0001515	81.87	gold quality
ascending aorta	UBERON:0001496	81.83	gold quality
layer of synovial tissue	UBERON:0007616	81.65	gold quality
descending thoracic aorta	UBERON:0002345	81.61	gold quality
tibial nerve	UBERON:0001323	81.03	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	29.81
E-HCAD-25	yes	15.51
E-ANND-3	yes	5.50

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

149 targeting UST, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734

Literature-anchored findings (GeneRIF, showing 4)

• 2OST transfers sulfate preferentially to the GlcA residue located in a unique sequence, -GalNAc(4SO(4))-GlcA-GalNAc(6SO(4))-. (PMID:16192264)
• analysis of differences and similarities various residues play in the biological roles of the HS-2OST and CS-2OST enzymes (PMID:17227754)
• Statistical analysis showed the strongest evidence for a variant located in an intron of UST associated with job-related exhaustion. (PMID:23620144)
• Results show that overexpression of 2OST alone in the HEK293 cells did not appreciably affect heparan sulfate (HS) chain length. Also, its simultaneous overexpression with Hsepi abolished the effect of Hsepi overexpression on the HS chain lengh. (PMID:27511124)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	usta	ENSDARG00000006044
danio_rerio	ustb	ENSDARG00000102715
mus_musculus	Ust	ENSMUSG00000047712
rattus_norvegicus	Ust	ENSRNOG00000016381
drosophila_melanogaster	pip	FBGN0003089

Paralogs (1): HS2ST1 (ENSG00000153936)

Protein

Protein identifiers

Uronyl 2-sulfotransferase — Q9Y2C2 (reviewed: Q9Y2C2)

Alternative names: Chondroitin sulfate 2-O-sulfotransferase

All UniProt accessions (1): Q9Y2C2

UniProt curated annotations — full annotation on UniProt →

Function. Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to the 2-OH position of uronyl residues in glycosaminoglycan chains. Has mainly activity toward iduronyl residues in dermatan sulfate, and toward glucuronyl residues of chondroitin sulfate. Has little to no activity toward desulfated N-resulfated heparin or N-sulfoheparosan.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Widely expressed.

Similarity. Belongs to the sulfotransferase 3 family.

RefSeq proteins (1): NP_005706* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005331	Sulfotransferase	Family
IPR007734	Heparan_SO4_2-O-STrfase	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF03567

UniProt features (27 total): mutagenesis site 14, glycosylation site 5, topological domain 2, chain 1, sequence variant 1, transmembrane region 1, region of interest 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2C2-F1	79.64	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 168

Glycosylation sites (5): 173, 319, 84, 140, 155

Mutagenesis-validated functional residues (14):

Position	Phenotype
109	severe reduction of sulfotransferase activity but no effect on 3’-phosphoadenylyl sulfate substrate binding; probably di
112	loss of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
113	severe reduction of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
115	loss of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
116	severe reduction of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
166	no loss of sulfotransferase activity.
167	some loss of sulfotransferase activity.
168	abolishes sulfotransferase activity but does not affect 3’-phosphoadenylyl sulfate substrate binding.
189	loss of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
197	severe reduction of sulfotransferase activity due to disruption of binding to the substrate 3’-phosphoadenylyl sulfate.
203	complete loss of sulfotransferase activity but only moderate reduction of 3’-phosphoadenylyl sulfate substrate binding;
206	complete loss of sulfotransferase activity but only moderate reduction of 3’-phosphoadenylyl sulfate substrate binding;
221	no effect on sulfotransferase activity.
321	severely abrogates sulfotransferase activity but does not affect 3’-phosphoadenylyl sulfate substrate binding; may be in

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2022870	CS-GAG biosynthesis
R-HSA-2022923	DS-GAG biosynthesis

MSigDB gene sets: 189 (showing top): GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, TATTATA_MIR374, GOBP_NEUROGENESIS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, TTGGGAG_MIR150, GOBP_CHONDROITIN_SULFATE_PROTEOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_ESTABLISHMENT_OF_CELL_POLARITY, chr6q25, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, ACATTCC_MIR1_MIR206, AACTTT_UNKNOWN

GO Biological Process (4): establishment of cell polarity (GO:0030010), chondroitin sulfate proteoglycan biosynthetic process (GO:0050650), dermatan sulfate proteoglycan biosynthetic process (GO:0050651), regulation of axonogenesis (GO:0050770)

GO Molecular Function (5): sulfotransferase activity (GO:0008146), chondroitin 2-sulfotransferase activity (GO:0034482), 3’-phosphoadenosine 5’-phosphosulfate binding (GO:0050656), dermatan 2-sulfotransferase activity (GO:0102142), transferase activity (GO:0016740)

GO Cellular Component (3): Golgi membrane (GO:0000139), membrane (GO:0016020), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Chondroitin sulfate/dermatan sulfate metabolism	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteoglycan biosynthetic process	2
protein O-linked glycosylation via xylose	2
establishment or maintenance of cell polarity	1
chondroitin sulfate proteoglycan metabolic process	1
dermatan sulfate proteoglycan metabolic process	1
axonogenesis	1
regulation of neuron projection development	1
regulation of anatomical structure morphogenesis	1
transferase activity, transferring sulphur-containing groups	1
chondroitin sulfotransferase activity	1
adenyl ribonucleotide binding	1
anion binding	1
sulfur compound binding	1
dermatan sulfotransferase activity	1
catalytic activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

334 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UST	HS3ST1	O14792	791
UST	NDST2	P52849	669
UST	NDST1	P52848	668
UST	DSE	Q9UL01	580
UST	EXT1	Q16394	571
UST	GLCE	O94923	564
UST	HS3ST3B1	Q9Y662	555
UST	EXT2	Q93063	548
UST	NDST3	O95803	544
UST	HS3ST4	Q9Y661	532
UST	HS3ST5	Q8IZT8	526
UST	HS3ST2	Q9Y278	502
UST	HS3ST3A1	Q9Y663	501
UST	CHST12	Q9NRB3	497
UST	EXTL3	O43909	486

IntAct

22 interactions, top by confidence:

A	B	Type	Score
UST	GOLIM4	psi-mi:“MI:0914”(association)	0.530
MRAP2	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
MRAP2	PODXL	psi-mi:“MI:0914”(association)	0.530
UST	CANX	psi-mi:“MI:0914”(association)	0.530
Dlg4	UST	psi-mi:“MI:0407”(direct interaction)	0.440
UST	PCYOX1	psi-mi:“MI:0915”(physical association)	0.400
UST	ADRB2	psi-mi:“MI:0915”(physical association)	0.370
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
MRAP2	GOSR1	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
EFNA4	NBAS	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
PIGN	GPR89A	psi-mi:“MI:0914”(association)	0.350
TMEM59	GPR89A	psi-mi:“MI:0914”(association)	0.350
SCARA5	COLGALT2	psi-mi:“MI:0914”(association)	0.350
UST	NMU	psi-mi:“MI:0914”(association)	0.350
SLC27A6	NBAS	psi-mi:“MI:0914”(association)	0.350
SLC30A7	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC49A4	AP3B1	psi-mi:“MI:0914”(association)	0.350
MYC	UST	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (57): UST (Affinity Capture-MS), SLC27A6 (Affinity Capture-MS), INHBE (Affinity Capture-MS), PPT2 (Affinity Capture-MS), CANX (Affinity Capture-MS), DCAKD (Affinity Capture-MS), PON2 (Affinity Capture-MS), GLG1 (Affinity Capture-MS), GOLIM4 (Affinity Capture-MS), XYLT2 (Affinity Capture-MS), MAN1A1 (Affinity Capture-MS), JAG2 (Affinity Capture-MS), OCIAD1 (Affinity Capture-MS), LDLR (Affinity Capture-MS), IMPAD1 (Affinity Capture-MS)

ESM2 similar proteins: A0A8C2LVE3, A2BGL3, F4HXW9, O08889, O17645, O43909, O43916, O93336, O93403, O95461, P25722, P69478, P79948, Q0IIY2, Q2TBF2, Q5NDE4, Q5NDE5, Q5NDE6, Q5NDE7, Q5NDE8, Q5NVB3, Q5R621, Q5RJQ0, Q5XHM7, Q66PG1, Q66PG2, Q66PG3, Q6DBY9, Q6NVP8, Q6P9A2, Q6PA90, Q76EC5, Q76KB1, Q7LFX5, Q7LGA3, Q7LGC8, Q7T3S3, Q800H9, Q8BUB6, Q8CHI9

Diamond homologs: A0A8C2LVE3, O08889, O17645, O93336, P25722, Q5R621, Q76KB1, Q7LGA3, Q86BJ3, Q8BUB6, Q8R3H7, Q9Y2C2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2912 predictions. Top by Δscore:

Variant	Effect	Δscore
6:148747675:TGGGT:T	donor_loss	1.0000
6:148747676:GG:G	donor_gain	1.0000
6:148747676:GGGTA:G	donor_loss	1.0000
6:148747677:GG:G	donor_gain	1.0000
6:148747677:GGTA:G	donor_loss	1.0000
6:148747678:G:C	donor_loss	1.0000
6:148747679:T:G	donor_loss	1.0000
6:148831297:G:GT	donor_gain	1.0000
6:148886980:TTCTA:T	acceptor_loss	1.0000
6:148886981:TCTAG:T	acceptor_loss	1.0000
6:148886982:CTAGG:C	acceptor_loss	1.0000
6:148886983:TAGG:T	acceptor_loss	1.0000
6:148886984:A:AG	acceptor_gain	1.0000
6:148886984:A:C	acceptor_loss	1.0000
6:148886984:AG:A	acceptor_gain	1.0000
6:148886985:G:GG	acceptor_gain	1.0000
6:148886985:GG:G	acceptor_gain	1.0000
6:148887028:AGGTA:A	donor_loss	1.0000
6:148887030:GTAA:G	donor_loss	1.0000
6:148887031:T:G	donor_loss	1.0000
6:148941274:CCCA:C	acceptor_loss	1.0000
6:148941275:CCAG:C	acceptor_loss	1.0000
6:148941276:CAGG:C	acceptor_loss	1.0000
6:148941277:A:T	acceptor_loss	1.0000
6:148941278:G:A	acceptor_loss	1.0000
6:148941431:ACAA:A	donor_gain	1.0000
6:148941432:CAA:C	donor_gain	1.0000
6:148941432:CAAGT:C	donor_loss	1.0000
6:148941433:AA:A	donor_gain	1.0000
6:148941433:AAG:A	donor_loss	1.0000

AlphaMissense

2676 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:148941306:T:G	Y107D	1.000
6:148941311:C:A	N108K	1.000
6:148941311:C:G	N108K	1.000
6:148941313:G:C	R109T	1.000
6:148941313:G:T	R109M	1.000
6:148941314:G:C	R109S	1.000
6:148941314:G:T	R109S	1.000
6:148941318:G:C	G111R	1.000
6:148941318:G:T	G111C	1.000
6:148941319:G:A	G111D	1.000
6:148941319:G:T	G111V	1.000
6:148941321:A:C	K112Q	1.000
6:148941321:A:G	K112E	1.000
6:148941322:A:C	K112T	1.000
6:148941322:A:T	K112M	1.000
6:148941323:G:C	K112N	1.000
6:148941323:G:T	K112N	1.000
6:148941324:T:C	C113R	1.000
6:148941325:G:A	C113Y	1.000
6:148941325:G:T	C113F	1.000
6:148941326:T:G	C113W	1.000
6:148941327:G:T	G114W	1.000
6:148941328:G:A	G114E	1.000
6:148941330:A:C	S115R	1.000
6:148941331:G:T	S115I	1.000
6:148941332:C:A	S115R	1.000
6:148941332:C:G	S115R	1.000
6:148941334:G:C	R116P	1.000
6:148941433:A:C	Q149P	1.000
6:148953879:T:C	L152P	1.000

dbSNP variants (sampled 300 via entrez): RS1000005208 (6:148818007 C>T), RS1000033127 (6:149046740 G>A), RS1000056751 (6:148774971 T>C), RS1000061724 (6:148863317 G>A), RS1000078274 (6:149065234 G>A,T), RS1000085951 (6:148768996 G>A), RS1000119488 (6:148927106 A>G), RS1000119707 (6:148996651 A>G), RS1000119795 (6:148913479 A>C,G), RS1000148692 (6:148946202 A>G), RS1000152056 (6:148767294 A>C), RS1000170331 (6:148749701 A>G), RS1000170508 (6:148996457 G>T), RS1000181649 (6:149011513 G>T), RS1000186725 (6:148843844 T>C)

Disease associations

OMIM: gene MIM:610752 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST000643_4	Response to antidepressants	9.000000e-06
GCST000643_8	Response to antidepressants	4.000000e-08
GCST001983_1	Job-related exhaustion	7.000000e-07
GCST002681_5	Post-traumatic stress disorder	2.000000e-06
GCST006061_208	Atrial fibrillation	8.000000e-17
GCST006061_209	Atrial fibrillation	3.000000e-17
GCST006111_2	Diastolic blood pressure x sodium interaction (2df test)	7.000000e-09
GCST006112_1	Diastolic blood pressure x sodium interaction (1df test)	3.000000e-09
GCST006414_120	Atrial fibrillation	1.000000e-24
GCST006585_2763	Blood protein levels	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0009282	sodium measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2500535	Efficacy	3	nortriptyline	Major Depressive Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2500535	UST	3	0.00	1	nortriptyline

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, decreases expression	4
bisphenol A	decreases methylation, increases expression	2
sodium arsenite	affects splicing, decreases expression, increases expression	2
Acetaminophen	increases expression	2
Aflatoxin B1	affects methylation, decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, decreases expression	1
diallyl trisulfide	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
ICG 001	increases expression	1
bisphenol S	decreases methylation	1
Resveratrol	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Panobinostat	affects expression, affects cotreatment	1
Air Pollutants	decreases expression, increases abundance	1
Calcitriol	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, affects expression	1
Coumestrol	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Methyl Methanesulfonate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.